Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-01 21:40:20 - browse：5

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Patient advocates sound warning on FDA proposal on salt intake

entertainment

WSS

Ed Silverman on new gene therapies, biosimilars, coffee, and more

FDA approves first treatment for ultra

Eye stem cell transplant could help restore vision in injured people

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

entertainment

Wikipedia

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Congress must give Medicare recipients genetic counseling access

How one medical school became remarkably diverse

Living with Hashimoto's and celiac disease, and med school, too

In age of alternative facts, a scholarly course on calling out crap

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

After affirmative action ruling, medical educators look to 'holistic review'

Cancer drug shortages' outsize impact on ovarian cancer patients

entertainment

Alabama IVF ruling threatens families facing fatal genetic disease

With competition flaring, obesity drug hits goal in liver disease study

Trump cancels press conference intended to dispute Georgia election interference charges

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

New definition of a human embryo proposed amid rapid advances

Medicare inequities exacerbate Puerto Rico’s health disparities

knowledge

hotspot

entertainment

focus